34 results about "Hepcidin" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of hepcidin expression quantity in larimichthys crocea liver as larimichthys crocea visceral white-spot disease resistance evaluation index and a construction method. The hepcidin expression quantity in the larimichthys crocea liver is applied as the larimichthys crocea visceral white-spot disease resistance evaluation index. The construction method of the resistance evaluation index comprises the following steps: taking healthy small yellow croaker intraperitoneal injection pseudomonas proteinus strain bacterial liquid, and determining a half lethal dose in 96 hours; the method comprises the following steps: injecting a half lethal dose of bacterial liquid of pseudomonas proteinus strains into the abdominal cavity of healthy small yellow croaker for 96 hours, and after infection, taking different tissues to carry out hepcidin gene expression fluorescent quantitative PCR analysis; a regression model of gene expression quantity and bacterium loading quantity is established through fluorescence quantification, and the relationship between hepcidin expression quantity and disease resistance is constructed. Accurate disease-resistant phenotype information is provided for development of breeding of visceral white-spot disease-resistant improved varieties of the small yellow croakers, the accuracy of disease-resistant breeding is promoted, early detection of diseases is realized, and prevention and treatment of the diseases are effectively guided.

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

The present disclosure encompasses pharmaceutical compositions or formulations of hepcidin peptide analogues or mimetics, as well as to the use of the formulations in the treatment and / or prevention of a variety of diseases, conditions, or disorders, including the treatment and / or prevention of iron overload diseases including hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.

Methods of increasing systemic iron availability in a human subject using plant-derived ferritin-bound iron are provided. In certain embodiments, ferritin-bound iron is orally administered in an amount effective to produce sustained systemic iron exposure characterized by measurable serum iron levels at least 24 hours after administration. In some embodiments, administration produces a delayed peak serum iron concentration and provides controlled systemic iron delivery relative to conventional iron supplements. In certain embodiments, administration of ferritin-bound iron results in a reduced hepcidin response relative to ferrous sulfate, thereby facilitating improved iron utilization. The ferritin-bound iron may be absorbed through receptor-mediated uptake mechanisms that provide controlled intracellular iron release and sustained systemic availability. The methods are useful for increasing systemic iron availability and for treating or preventing iron deficiency and iron deficiency anemia in human subjects.

The invention provides micropterus salmoides Hepcidin-1 (Ms-Hepcidin-1) and an application of a synthetic polypeptide of the micropterus salmoides Hepcidin-1 in preparation of an anti-fish virus drug. The research finds that the Ms-Hepcidin-1 synthetic polypeptide has a remarkable antiviral effect and is a novel antibacterial peptide with a function of inhibiting fish viruses. The Ms-Hepcidin-1 synthetic polypeptide and the recombinant eukaryotic expression vector of the Ms-Hepcidin-1 synthetic polypeptide can obviously reduce the transcription level of MCP, MMP and DNMT genes and the MCP protein level of LMBV, inhibit the replication of the LMBV and reduce the virus titer, and have an obvious fish virus resisting effect. Moreover, the polypeptide synthesized by Ms-Hepcidin-1 is simple to prepare, low in cost, safe to use and convenient to preserve, can be used as a novel antiviral functional gene product to prepare antiviral drugs for fishes, and has important significance on prevention and control of fish iridovirus diseases.

The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in a specific population of non-dialysis subjects with anemia associated with chronic kidney disease, characterized by baseline hepcidin and hsCRP levels.

Aspects of the present disclosure provide anti-TMPRSS6 antibodies and methods of using the same to promote hepcidin expression and treat iron overload related disorders such as hemopigmentation, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), and blood transfusion.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

This invention provides the application of Hepcidin-1 (Ms-Hepcidin-1) and its synthetic polypeptide in the preparation of antiviral drugs for largemouth bass. The invention reveals that the Ms-Hepcidin-1 synthetic polypeptide exhibits significant antiviral activity and is a novel antimicrobial peptide with the function of inhibiting fish viruses. Both the Ms-Hepcidin-1 synthetic polypeptide and its recombinant eukaryotic expression vector can significantly reduce the transcriptional levels of MCP, MMP, and DNMT genes and the MCP protein level of LMBV, inhibit LMBV replication, and reduce viral titers, demonstrating significant antiviral activity against fish viruses. Furthermore, the polypeptide synthesized from Ms-Hepcidin-1 is simple to prepare, low in cost, safe to use, and easy to store. As a novel antiviral functional gene product, it can be applied to the preparation of antiviral drugs for fish, which is of great significance for the prevention and control of iridovirus disease in fish.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

The present invention discloses an adsorbent for removing excess hepcidin and a preparation method thereof. The adsorbent for removing excess hepcidin is made by using EDTA as a cross-linking agent to form cross-linked chitosan microspheres embedded with zirconium phosphate and / or zirconium oxide, and L-glutathione is bonded to the surface of the cross-linked chitosan microspheres. The adsorbent for removing excess hepcidin of the present invention uses chitosan microspheres as a carrier, and while the microspheres are cross-linked, further bonding ligands are introduced, eliminating the need for additional cross-linking agents and ligands. The reaction conditions are mild, the preparation method is simple, and the cross-linked microspheres have suspended carboxyl groups, which can be further coupled with peptides and amino acids to achieve functional modification. The microspheres can withstand high-temperature steam sterilization and effectively remove excess hepcidin and urea nitrogen from the blood.

The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP or hepcidin inhibitors.

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and / or prevention of a variety of diseases, conditions or disorders, including treatment and / or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

The application discloses application of a Hepcidin modulator. Abnormal increase of Hepcidin in a ventral hippocampus region in a senescence process drives imbalance of iron homeostasis of neurons, and further induces an anxiety-like phenotype. Pharmacodynamic verification shows that administration of a Hepcidin inhibitor to cells of the ventral hippocampus can effectively reverse anxiety behavior of a senescence model animal. The pharmaceutical composition described in the application takes the Hepcidin pathway as an intervention target, and an active ingredient thereof is selected from the following: (1) a high-affinity Hepcidin inhibitor NOX-H94; and (2) a recombinant adeno-associated virus vector carrying a Hepcidin-targeted interference sequence, which is used for silencing expression of Hepcidin in neurons of the ventral hippocampus in vivo. The above-mentioned preparation provides a new molecular target and a drug candidate for clinical intervention of senescence-related emotional disorders.

The present invention provides methods for treating hepcidin-mediated disorders.

The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.

The application relates to a hepcidin chemiluminescence immunoassay kit and a non-diagnostic method for detecting hepcidin, the kit comprising a calibrator, a quality control, an integrated bifunctional antibody reagent, a magnetic particle reagent, a cleaning solution and a chemiluminescence substrate solution; the integrated bifunctional antibody reagent is a buffer containing HEP-specific antibodies covalently connected with fluorescein isothiocyanate and alkaline phosphatase through pH-sensitive connecting bonds; the magnetic particle reagent is a magnetic microsphere suspension coated with a goat anti-fluorescein isothiocyanate antibody; the cleaning solution is a buffer containing a surfactant composition, and the surfactant composition comprises nonionic surfactants, zwitterionic surfactants and high-molecular nonionic surfactants. The hepcidin chemiluminescence immunoassay kit has the effects of ultra-low background noise, ultra-high sensitivity, ultra-wide linear range and simplified operation of end users by means of the integrated bifunctional antibody reagent and the surfactant composition cleaning solution.

The present invention discloses the use of a composition for preparing an iron-supplementing preparation. The composition comprises cornus officinalis and / or a cornus officinalis extract, and mangosteen and / or a mangosteen extract. By combining the active ingredients, the present invention provides a composition that can promote the body's absorption of iron by promoting intestinal iron absorption and / or inhibiting hepcidin, thereby providing an iron-supplementing effect. The composition can further be used to treat functional iron deficiency and other indications, providing a more effective preparation for improving iron deficiency. Furthermore, the preparation prepared using the composition also has the effects of regulating physical constitution, replenishing deficiency and invigorating qi, and regulating the body's health.

The present invention provides peptides, which are hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.

Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and / or conditions associated with hepcidin deficiency or suppression.

This invention provides a method for treating anemia in subjects with myelofibrosis. [Solution] A method is provided for treating anemia in a subject with myelofibrosis, comprising administering an effective amount of a hemoduvelin-induced BMP signaling antagonist, a hepcidin antagonist, to the subject.

Aspects of the application provide siRNAs that target and reduce the expression of hemochromatosis type 2 (HFE2), compositions and methods of using the same to reduce serum hepcidin concentration and treat anemias of inflammation, iron-restricted anemias and / or conditions associated with anemia.

The present invention belongs to the technical field of medicine. Disclosed in the present invention is a new pharmaceutical use of hepcidin, specifically the use of hepcidin in the preparation of a drug for blocking ferroptosis of a collecting tubule in acute kidney injuries and protecting kidney function. It has been demonstrated in the present invention that both renal endogenous and exogenous hepcidin can alleviate tubular injury and improve renal function in ischemia-reperfusion-induced acute kidney injury by inhibiting ferroptosis in intercalated cells of the collecting tubule. Disclosed in the present invention is a drug for alleviating ferroptosis of a collecting tubule and protecting kidney function in ischemic-reperfusion-induced acute kidney injury. The drug is an intraperitoneal injection prepared by dissolving hepcidin at a therapeutic concentration in PBS.

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

The present disclosure provides small molecule compounds that are hepcidin mimetics. In addition, the present disclosure also encompasses pharmaceutical compositions that include the small molecule compounds and a pharmaceutically acceptable carrier, excipient or vehicle. The present disclosure also encompasses kits that include the small molecule compounds or the pharmaceutical compositions. The present disclosure also encompasses methods of using the hepcidin mimetic compounds.

In the present invention, we identified the hepatokine FGL1 as a previously unreported hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deficiency of Fgl1 in mice (Fgl1- / -) results in lower hepcidin repression after hemorrhage. Finally, we clearly demonstrated that FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the canonical BMP-SMAD signaling cascade that controls hepcidin regulation. Therefore, the present invention relates to methods for preventing or treating iron overload-related diseases by targeting the hepatokine FGL1, a novel hepcidin repressor.

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.